Abstract
Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinase signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of several neoplasms, including lung, breast, kidney and pancreatic cancer as well as gastro-intestinal stromal tumors and chronic myeloid leukemia. This comprehensive review focuses on the most relevant members of the first and the second generation TKIs designed to interact with receptor and nonreceptor TKs. Attention is mainly focused on molecular mechanisms in in vitro and in vivo models related to the clinical activity of the drugs and to the development of resistance to treatment, still the major challenge in cancer research and care.
Keywords: Angiogenesis, HER family, multitarget, nonreceptors, receptors, resistance, tyrosine kinase inhibitors
Current Cancer Drug Targets
Title: Tyrosine Kinase Inhibitors
Volume: 10 Issue: 5
Author(s): C. Natoli, B. Perrucci, F. Perrotti, L. Falchi and S. Iacobelli
Affiliation:
Keywords: Angiogenesis, HER family, multitarget, nonreceptors, receptors, resistance, tyrosine kinase inhibitors
Abstract: Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinase signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of several neoplasms, including lung, breast, kidney and pancreatic cancer as well as gastro-intestinal stromal tumors and chronic myeloid leukemia. This comprehensive review focuses on the most relevant members of the first and the second generation TKIs designed to interact with receptor and nonreceptor TKs. Attention is mainly focused on molecular mechanisms in in vitro and in vivo models related to the clinical activity of the drugs and to the development of resistance to treatment, still the major challenge in cancer research and care.
Export Options
About this article
Cite this article as:
Natoli C., Perrucci B., Perrotti F., Falchi L. and Iacobelli S., Tyrosine Kinase Inhibitors, Current Cancer Drug Targets 2010; 10 (5) . https://dx.doi.org/10.2174/156800910791517208
DOI https://dx.doi.org/10.2174/156800910791517208 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Exploring Nanotechnologies for the Effective Therapy of Malaria Using Plant-Based Medicines
Current Pharmaceutical Design The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Potential Impacts of Prebiotics and Probiotics on Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Editorial (Thematic Issue: Microglia - A Therapeutic Target in Neurological Diseases and Disorders)
CNS & Neurological Disorders - Drug Targets Synthetic and Biological Vesicular Nano-Carriers Designed for Gene Delivery
Current Pharmaceutical Design Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems
Current Gene Therapy Copper Compounds in Cancer Chemotherapy
Current Medicinal Chemistry Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging Poly(lactide-co-glycolide)-based Micro and Nanoparticles for the Controlled Drug Delivery of Vitamins
Current Nanoscience How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments
Current Pharmaceutical Design Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Abnormal Choline Phospholipid Metabolism in Breast and Ovary Cancer:Molecular Bases for Noninvasive Imaging Approaches
Current Medical Imaging Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology Amyloid Precursor Protein Processing in Vivo - Insights from a Chemically- Induced Constitutive Overactivation of Protein Kinase C in Guinea Pig Brain
Current Medicinal Chemistry